Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

NEXT STORY
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
PREV STORY
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia

author_avatar
NASDAQ Market News

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

author_avatar
NASDAQ Market News

ERYTECH annuncia l’abstract con i risultati dello studio di fase 2 su eryaspase per la leucemia linfoblastica acuta, selezionato per la presentazione orale al convegno annuale dell’American Society of Hematology 2020

author_avatar
NASDAQ Market News